Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2002 pubmed 80 citations

Humanin inhibits cell death of serum-deprived PC12h cells.

Kariya. Shingo S; Takahashi. Nobuyuki N; Ooba. Naoki N; Kawahara. Makoto M; Nakayama. Hitoshi H; Ueno. Satoshi S

Key Findings

  • Humanin and S14G‑humanin prevent death of PC12 cells under serum‑deprivation
  • Protection was confirmed using three assays: cell viability (MTS), caspase‑3 activity, and DNA fragmentation
  • Results hint that humanin could have broad cytoprotective effects beyond Alzheimer’s models

Practical Outcomes

  • For biohackers, this indicates humanin may act as a general cell‑protective agent, but the evidence is limited to cell‑culture experiments. No human dosing or safety data are available yet, so it’s not ready for direct supplementation protocols. Keep an eye on future studies for dosage guidance and real‑world applicability.

Summary

The study shows that the small protein humanin and a stronger version called S14G‑humanin can keep a type of nerve‑like cells alive when they’re starved of nutrients, suggesting these peptides might protect cells from many kinds of stress, not just Alzheimer‑related damage.

Abstract

Humanin (HN) and S14G HN (HNG) are recently discovered polypeptides that rescue cells from death induced by multiple different types of familial Alzheimer's disease genes and by amyloid-beta. However, the cytoprotective activity of these peptides against other cell death-inducing stimuli remains unclear. In this study, we demonstrated, using three different methods (MTS assay, caspase-3 assay, and detection of DNA fragmentation), that both HN and HNG protect PC12 cells from death elicited by serum deprivation. This implies the potential of the peptides to rescue cells from a broad spectrum, if not all, of cell death-inducing factors. Further investigations on HN may lead the possible application of this peptide as therapeutic agent for the treatment of other neurodegenerative diseases.

Study Information

Provider

pubmed

Year

2002

Date

2002-05-07T00:00:00.000Z

DOI

10.1097/00001756-200205070-00034

Citations

80

References

25